Skip to main content
Premium Trial:

Request an Annual Quote

CAT Posts Narrowed Revenue, Widened Loss in Q1

NEW YORK, Feb. 25 - Cambridge Antibody Technology on Monday reported significantly widened loss in its first quarter 2002 atop slightly thinned revenue.


For the period ended Dec. 31, CAT said that total revenue came to £1.9 million, or roughly $2.7 million, compared with £2.0 million one year ago.

R&D spending in the quarter, which reached £6.1 million compared with £4.7 million one year ago, led total operating costs of £7.7 million, compared with £6.3 million one year ago, CAT said.


As a result, the company posted a nearly doubled net, which it said was £4.0 million in the current quarter compared with £1.9 million year over year.


Earlier on Monday, CAT said that it had hired Peter Chambre, Celera's former chief operating officer, to replace David Chiswell as CEO. He is slated to start sometime in April.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.